Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management

Front Immunol. 2024 Mar 22:15:1375497. doi: 10.3389/fimmu.2024.1375497. eCollection 2024.

Abstract

Neurological immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI) are rare complications of immunotherapy, particularly dreadful for patients and clinical teams. Indeed, neurological irAEs are potentially severe and their diagnosis require prompt recognition and treatment. Additionally, the spectrum of neurological irAEs is broad, affecting either neuromuscular junction, peripheral or central nervous system. Here, we described the case of a 55-year man with metastatic melanoma, facing a brutal right peripheral cerebral palsy after his third ipilimumab/nivolumab infusion. After the case presentation, we reviewed the literature about this rare complication of immunotherapy, and described its diagnosis work-up and clinical management.

Keywords: cerebral palsy; immune checkpoint inhibitors; immune toxicity; ipilimumab; neurological toxicity; nivolumab.

Publication types

  • Review
  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Facial Paralysis* / chemically induced
  • Facial Paralysis* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Ipilimumab / therapeutic use
  • Male
  • Melanoma*
  • Nivolumab / therapeutic use

Substances

  • Nivolumab
  • Immune Checkpoint Inhibitors
  • Ipilimumab

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Our work is supported by Paoli-Calmettes Institute and Aix-Marseille University.